The Oxford University COVID-19 vaccine undergoing Phase III clinical trials with British pharma giant AstraZeneca is doing 'everything expected' which means good news in the fight against the......
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is......
The coronavirus vaccine developed by Oxford University and AstraZeneca “should be” effective against the highly transmissible new strain of the virus, a United Kingdom media report said......
Vaccine major Serum Institute of India on Thursday said the COVID-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly......
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its COVID vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the......
Serum Institute of India chief Adar Poonawalla will pay £138 million (about Rs 1,444 crore) for a Mayfair mansion in London in one of the city’s most expensive home sales of the year,......
'The challenge will be making sure its efficacy is high.''If a vaccine is only 50 to 60 per cent efficient, it's a double-edged sword.' Adar Poonawalla, chief executive officer, Serum Institute of......
Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine.Sohini Das profiles its 39-year-old CEO. IMAGE: Adar Poonawalla, right, and his father Dr Cyrus S......
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford......
The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured. India plans to create a digital......